Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McGill University
$105,000.00
Bioinformatics integration of different genomic data to predict and understand resistance to FOLFOX and anti-VEGF treatment in the context of metastatic colorectal cancer.
FY 2011-12
Summary
Since President Nixon signed the National Cancer Act in 1971 our understanding of cancer has increased tremendously. Unfortunately, cancer still remains the most devastating disease faced by Canadians. Great hopes are now placed on a new generation of extremely efficient drugs designated to target specific types of cancer. Although highly efficient, their cost is prohibitive, easily exceeding $25K for even short treatments. Moreover, only a subset of patients respond positively to such treatments. The community currently lacks any form of biomarker to accurately predict who will and will not respond.
Within Q-CROC, a Québec-wide effort to understand cancer resistance to treatment, our goal is to develop a clinical test that will stratify cancer patients into responder and non-responder classes. This test is built from samples of cancer patients prior to any treatment using a number of new technologies like microarrays and next generation sequencing. This PhD project is focused on the application of bioinformatics and biostatistics to identify a set of genes that jointly predict whether a patient will respond or not to specific compounds. The genes within the predictor will be subjected to extensive analysis, in order to understand better the underlying cancer biology that distinguish between responders and non-responders. An accurate gene set predictor in this setting would reduce the number of patients suffering needlessly from anti-cancer drugs that are ineffective for their personal genome, and reduce the cost of health care.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
257516
Name
Paquet Éric R
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Bioinformatics integration of different genomic data to predict and understand resistance to FOLFOX and anti-VEGF treatment in the context of metastatic colorectal cancer.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Biostatistics; Data Integration; Drug Resistance; Genomics; Metastatic Colorectal Cancer
Abstract
Since President Nixon signed the National Cancer Act in 1971 our understanding of cancer has increased tremendously. Unfortunately, cancer still remains the most devastating disease faced by Canadians. Great hopes are now placed on a new generation of extremely efficient drugs designated to target specific types of cancer. Although highly efficient, their cost is prohibitive, easily exceeding $25K for even short treatments. Moreover, only a subset of patients respond positively to such treatments. The community currently lacks any form of biomarker to accurately predict who will and will not respond.
Within Q-CROC, a Québec-wide effort to understand cancer resistance to treatment, our goal is to develop a clinical test that will stratify cancer patients into responder and non-responder classes. This test is built from samples of cancer patients prior to any treatment using a number of new technologies like microarrays and next generation sequencing. This PhD project is focused on the application of bioinformatics and biostatistics to identify a set of genes that jointly predict whether a patient will respond or not to specific compounds. The genes within the predictor will be subjected to extensive analysis, in order to understand better the underlying cancer biology that distinguish between responders and non-responders. An accurate gene set predictor in this setting would reduce the number of patients suffering needlessly from anti-cancer drugs that are ineffective for their personal genome, and reduce the cost of health care.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Paquet, Éric R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~